AMONG 17 INDUCERS OF DIFFERENTIATION ONLY SODIUM-BUTYRATE CAUSES A PERMANENT DOWN-REGULATION OF C-MYC IN BURKITTS-LYMPHOMA

被引:10
作者
ROTTLEB, C
BORNKAMM, GW
POLACK, A
机构
[1] GSF MUNICH, INST KLIN MOLEK BIOL & TUMORGENET, D-81377 MUNICH, GERMANY
[2] STADT KRANKENHAUS MUNCHEN BOGENHAUSEN, D-81925 MUNICH, GERMANY
关键词
D O I
10.1002/ijc.2910620609
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
De-regulation of c-myc by chromosomal translocation is one crucial step for the development of Burkitt's lymphoma. The de-regulation is caused through juxtaposition of c-myc with one of the 3 immunoglobulin loci. We have reported earlier that treatment of Burkitt's lymphoma cells with n-butyrate causes transcriptional down-regulation of c-myc expression. Because of the possible therapeutic implication of this result, we looked for other compounds which, on the one hand, might be applicable in vivo and, on the other hand, might cause down-regulation of c-myc expression in Burkitt's lymphoma cells. Since n-butyrate is known to induce differentiation, we have examined other differentiation inducers of different chemical nature for their ability to reduce c-myc expression in Burkitt's lymphoma cells. Many of the substances tested caused down-regulation of c-myc expression, which, however, was transient except for n-butyrate. Three types of compounds proved to be particularly active: polar planar compounds (e.g., dimethylsulfoxide), heterocyclic compounds (e.g., hypoxanthine), and short-chain fatty acids (e.g., n-butyric acid). The action of n-butyrate on c-myc supression was exceptional not only in not being transient, but also in being allele-specific: it down-regulated the translocated allele without affecting the normal one. Medium transfer experiments revealed that neither degradation of the active compound nor an intracellular resistance mechanism can fully account for the reversibility of c-myc down-regulation after treatment with the transiently acting polar planar compounds. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:697 / 702
页数:6
相关论文
共 35 条
[31]   RETINOIDS IN CANCER-THERAPY [J].
SMITH, MA ;
PARKINSON, DR ;
CHESON, BD ;
FRIEDMAN, MA .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :839-864
[32]   HOLD BACK OF RNA POLYMERASE-II AT THE TRANSCRIPTION START SITE MEDIATES DOWN-REGULATION OF C-MYC INVIVO [J].
STROBL, LJ ;
EICK, D .
EMBO JOURNAL, 1992, 11 (09) :3307-3314
[33]   INDUCTION OF ERYTHROID DIFFERENTIATION IN MURINE VIRUS-INFECTED ERYTHROLEUKEMIA CELLS BY HIGHLY POLAR COMPOUNDS [J].
TANAKA, M ;
LEVY, J ;
TERADA, M ;
BRESLOW, R ;
RIFKIND, RA ;
MARKS, PA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (03) :1003-1006
[34]  
WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490
[35]  
YOSHIDA M, 1990, J BIOL CHEM, V265, P17174